Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levobupivacaine + iohexol
- Development stage
- Unknown
- Lead developer
- National Taiwan University Hospital
- Modality
- Small Molecules
- Administration
- Perineural
01
Overview
This intervention refers to a specific analgesic combination used by the National Taiwan University Hospital for ultrasound-guided Erector Spinae Plane Block (ESPB). It consists of levobupivacaine (marketed as Chirocaine), a long-acting local anesthetic, and iohexol (marketed as Omnipaque), a non-ionic, water-soluble radiographic contrast medium. Levobupivacaine, the S-enantiomer of bupivacaine, works by binding to the intracellular portion of voltage-gated sodium channels, blocking the influx of sodium ions into nerve cells and preventing the depolarization and propagation of pain signals. Iohexol is added to the mixture to allow for the visualization of the local anesthetic's spread within the fascial plane under imaging. This combination is primarily investigated for providing postoperative analgesia in patients undergoing radiofrequency ablation for hepatocellular carcinoma.
- Other names
- levobupivacaine and iohexol
02
Targets
Kir (Inward-rectifier potassium channels)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)SCN8A (NaV1.6)SCN9A (Sodium channel protein type 9 subunit alpha)
Beyond the preview
Go deeper on levobupivacaine + iohexol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levobupivacaine + iohexol.